Phase I Clinical Trial in Healthy Adult

Condition:   COVID-19 Intervention:   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Sponsors:   CanSino Biologics Inc.;   Beijing Institute of Biotechnology;   Jiangsu Province Centers for Disease Control and Prevention;   Hubei Provincial Center for Disease Control and Prevention;   Tongji Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials